Other inflammatory pathways, such as NLRP3 inflammasome or TLR4 pathways, became a therapeutic target due to its role in pro-inflammatory cytokines production in AD and PD (Fellner et al., 2013; Heneka et al., 2013; Burguillos et al., 2015). The gene discussed is TLR4; the disease is Parkinson disease.